Are we PREPAREd? Concerning the “PREemptive Pharmacogenomics Testing for Preventing Adverse Drug Reactions (PREPARE) Study”

Ana de Carmo Campos; Maria Luís Cardoso; Astrid Vicente

doi:10.20344/amp.20170

Are we PREPAREd? Concerning the “PREemptive Pharmacogenomics Testing for Preventing Adverse Drug Reactions (PREPARE) Study”

Authors

Ana de Carmo Campos Serviço de Medicina III. Hospital Pulido Valente. Centro Hospitalar Universitário de Lisboa Norte. Lisboa; Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis. Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA). Lisboa.
Maria Luís Cardoso Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis. Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA). Lisboa; BioISI, Instituto de Biossistemas e Ciências Integrativas. Faculdade de Ciências da Universidade de Lisboa. Lisboa.
Astrid Vicente Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis. Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA). Lisboa; BioISI, Instituto de Biossistemas e Ciências Integrativas. Faculdade de Ciências da Universidade de Lisboa. Lisboa.

DOI:

https://doi.org/10.20344/amp.20170

Keywords:

Drug-Related Side Effects and Adverse Reactions, Pharmacogenomic Testing, Genomic Medicine

Abstract

N/a.

Downloads

Download data is not yet available.

References

Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. Ubiquitous pharmacogenomics consortium. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347-56.

Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24:350-62.

Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic factors and pharmacogenomics in adverse drug reactions. Int J Mol Sci. 2021;22:13302.

Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front Pharmacol. 2018;9:350.

Almeida F, Vicente AM, Calado P, Santos M, Carvalho AS, Águas C, et al. Estratégia Nacional para a Medicina Genómica - PT_MedGen: desafios e prioridades [relatórios científicos e técnicos]. Instituto Nacional de Saúde Doutor Ricardo Jorge, IP; 2022 [cited 2003 mai 20]. Available from: http://hdl.handle.net/10400.18/8259.

Downloads

Published

2023-10-02

How to Cite

de Carmo Campos A, Cardoso ML, Vicente A. Are we PREPAREd? Concerning the “PREemptive Pharmacogenomics Testing for Preventing Adverse Drug Reactions (PREPARE) Study”. Acta Med Port [Internet]. 2023 Oct. 2 [cited 2024 Nov. 22];36(10):689-90. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/20170

Download Citation

Issue

Vol. 36 No. 10 (2023): October

Section

Letters to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.